1.8597 0.11 (6.27%) | 02-06 11:45 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 3.65 | 1-year : | 4.75 |
Resists | First : | 3.13 | Second : | 4.07 |
Pivot price | 1.97 ![]() |
|||
Supports | First : | 1.61 | Second : | 1.33 |
MAs | MA(5) : | 1.74 ![]() |
MA(20) : | 2.01 ![]() |
MA(100) : | 11.04 ![]() |
MA(250) : | 73.22 ![]() |
|
MACD | MACD : | -0.4 ![]() |
Signal : | -0.4 ![]() |
%K %D | K(14,3) : | 5.9 ![]() |
D(3) : | 5.3 ![]() |
RSI | RSI(14): 39.8 ![]() |
|||
52-week | High : | 176 | Low : | 1.61 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ELAB ] has closed above bottom band by 36.0%. Bollinger Bands are 91.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 52 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 1.79 - 1.8 | 1.8 - 1.8 |
Low: | 1.67 - 1.68 | 1.68 - 1.69 |
Close: | 1.74 - 1.75 | 1.75 - 1.76 |
Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.
Wed, 27 Nov 2024
Elevai Labs announces 1-for-200 reverse stock split - Investing.com
Fri, 22 Nov 2024
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess - GlobeNewswire
Fri, 22 Nov 2024
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance - GlobeNewswire
Mon, 04 Nov 2024
Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 3 (M) |
Shares Float | 16 (M) |
Held by Insiders | 72.9 (%) |
Held by Institutions | 18.2 (%) |
Shares Short | 9,420 (K) |
Shares Short P.Month | 686 (K) |
EPS | -88.92 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.21 |
Profit Margin | -192.1 % |
Operating Margin | -231.6 % |
Return on Assets (ttm) | -88.6 % |
Return on Equity (ttm) | -351 % |
Qtrly Rev. Growth | 91.3 % |
Gross Profit (p.s.) | 0.55 |
Sales Per Share | 0.8 |
EBITDA (p.s.) | -1.56 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -6 (M) |
Levered Free Cash Flow | -4 (M) |
PE Ratio | -0.03 |
PEG Ratio | 0 |
Price to Book value | 8.09 |
Price to Sales | 2.21 |
Price to Cash Flow | -0.91 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |